The Systemic Shift: Rewriting the Rules of Specialty Pharmacy Networks

NATIONAL HARBOR, MD – September 24, 2026 – To understand the mechanics of modern healthcare, you must look past the hospital bed and the doctor’s office. You must look at the hidden infrastructure of distribution, financing, and regulatory definitions that dictate how life-saving treatments actually reach patients. This week, that infrastructure is undergoing a seismic stress test.

At the inSPire2026 Conference in National Harbor, Maryland, the National Association of Specialty Pharmacy (NASP) announced the election of eight new directors and the re-election of nine board members. But the routine governance update was overshadowed by a much larger, systemic mobilization. During his State of the Industry address, NASP Board Chair Scott Guisinger issued a stark call to action, launching a massive, data-driven advocacy campaign designed to shape the future of Medicare Part D contracting.

“This isn’t theoretical,” Guisinger told attendees. “The decisions being made now have the potential to shape the future of specialty pharmacy.”

The decisions Guisinger refers to are currently sitting on the desks of the Centers for Medicare & Medicaid Services (CMS). With billions of dollars and the survival of independent specialty pharmacies on the line, the industry is racing against a rapidly closing federal comment period to redefine what it means to be a specialty pharmacy—and how those entities are compensated for keeping our most complex patients alive.

The Regulatory Catalyst: CAA 2026

The urgency at inSPire2026 traces back to the halls of Congress and the recent passage of the Consolidated Appropriations Act, 2026 (CAA 2026). Among its sweeping provisions, Section 6223(a) of the legislation fundamentally altered the balance of power between pharmacies and Pharmacy Benefit Managers (PBMs).

For years, PBMs have operated with wide latitude under Medicare Part D’s "Any Willing Pharmacy" provisions. Historically, PBMs complied with these rules procedurally by offering uniform, non-negotiable contract templates across massive classes of pharmacies. Because specialty medications often cost tens of thousands of dollars per claim and require extensive clinical support—such as cold-chain shipping logistics, 24/7 patient monitoring, and complex prior authorizations—these standard contracts frequently forced independent and health-system pharmacies to accept reimbursement rates far below their actual acquisition and operational costs.

CAA 2026 changes the equation. The law explicitly directs the Secretary of Health and Human Services to establish binding, enforceable standards for what constitutes "reasonable and relevant" contract terms, effectively ending the era of arbitrary, one-size-fits-all PBM contracting. Furthermore, the legislation eliminates PBM spread pricing in Medicare Part D starting in 2028, requiring 100% pass-through of manufacturer rebates and restricting PBM compensation to flat-fee administrative services.

To implement these mandates, CMS recently issued Request for Information (RFI) CMS-4217-NC, opening a 60-day public comment window that closes on November 23, 2026. CMS is seeking empirical data to finalize these contract standards by April 2028. For NASP, this RFI represents a once-in-a-generation opportunity to codify the economic realities of their sector.

Redefining 'Specialty' Through Infrastructure

At the heart of the debate is a surprisingly simple question that has eluded federal regulators for two decades: What exactly is a specialty pharmacy?

Historically, CMS has avoided adopting a formal regulatory definition, allowing PBMs to define "specialty" based primarily on high-cost drug pricing thresholds. This drug-centric definition has enabled vertically integrated health insurers to route lucrative prescriptions to their own PBM-owned mail-order specialty units, effectively steering patients away from independent or hospital-based providers.

NASP is aggressively lobbying CMS to abandon the drug-tier definition in favor of an infrastructure-based standard. The association argues that specialty pharmacy should be defined by demonstrated clinical capabilities, operational systems, and rigorous third-party accreditation from bodies like URAC and ACHC.

If CMS adopts an accreditation-based definition, PBMs would be required to offer non-discriminatory, reasonable contracting terms to any pharmacy possessing the necessary clinical infrastructure to handle complex therapies. It shifts the power dynamic from the entity controlling the benefit to the entity providing the specialized care.

“There are fundamental principles around patient care, quality, access, and the value of specialty pharmacy where our collective voice can be incredibly powerful,” Guisinger noted. “That’s the opportunity NASP provides.”

The Antitrust Architecture of Evidence

Advocating for better reimbursement is easy; proving the systemic financial squeeze to federal regulators is a complex legal hurdle. To build a bulletproof, evidence-based docket for CMS, NASP has fully funded an initiative with the national healthcare law firm Frier Levitt.

The challenge Frier Levitt faces is immense. To prove that current PBM contracts are not "reasonable and relevant," they need real-world data on acquisition costs, dispensing fees, and operating margins. However, in 2023, the Department of Justice and the Federal Trade Commission officially withdrew longstanding antitrust safety zones for healthcare information sharing. Today, trade associations face heightened legal scrutiny when collecting industry financial data, as regulators are hyper-vigilant against price-signaling or horizontal coordination among competitors.

To bypass this antitrust minefield, Frier Levitt is operating as an independent, legally firewalled intermediary. Participating pharmacies—ranging from regional health systems to independent infusion providers—will submit proprietary data directly to the firm under strict confidentiality agreements. Frier Levitt will then scrub, normalize, and blindly aggregate the data into composite economic benchmarks.

No individual pharmacy, nor NASP leadership, will ever see the raw competitive data. The resulting de-identified economic evidence will be submitted to CMS under the protection of the Noerr-Pennington doctrine, which generally immunizes groups petitioning the government from antitrust liability.

Boardroom Realpolitik: A Coalition of Rivals

The sheer complexity of this data mobilization is mirrored by the composition of NASP’s own boardroom. A close look at the newly elected and re-elected directors reveals a fascinating coalition of industry rivals united by a shared regulatory threat.

Sitting at the same table are executives from independent specialty providers like Grant Knowles of Senderra, and health-system managers like Marc Choquette of St. Luke’s Health System. Yet, right alongside them are top executives from the very vertically integrated conglomerates that dominate the PBM space, including John Colaizzi of Walgreens, Lori Grebe of CenterWell Specialty Pharmacy, and Micaila Ruiz of Optum Rx.

This boardroom realpolitik highlights the intricate nature of the modern pharmacy ecosystem. While mega-corporations operate internal PBMs, their specialty pharmacy divisions still grapple with the same accreditation costs, clinical compliance mandates, and manufacturer distribution hurdles as the independents. By utilizing Frier Levitt’s blind data collection protocol, NASP ensures that this diverse board can aggressively advocate for reasonable clinical standards without triggering internal conflicts of interest or exposing sensitive corporate strategies.

“This is exactly why NASP exists—to bring the collective experience and expertise of this community into the conversations that will shape the future of specialty pharmacy,” Guisinger said. “But to do that effectively, we need our members engaged.”

As the November 23 deadline for CMS RFI CMS-4217-NC approaches, the specialty pharmacy sector is no longer waiting for the rules of the system to be handed down from above. By leveraging anonymized data, clinical accreditation, and an unlikely alliance of industry heavyweights, they are actively rewriting the code that governs access to the world's most advanced medicines. The outcome will not only determine the survival of independent pharmacies but will permanently alter the infrastructure of American healthcare delivery.